查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570679

5α 還原酶缺乏症市場：按類型、最終用戶、年齡層、診斷方法、治療 - 全球預測 2025-2030

5-Alpha Reductase Deficiency Market by Type (Primary 5-Alpha Reductase Deficiency, Secondary 5-Alpha Reductase Deficiency), End Users (Clinics, Hospitals, Research Institutes), Age Group, Diagnosis Technique, Treatment - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年5α-還原酶缺乏症市值為11.7億美元，預計到2024年將達到12.8億美元，複合年成長率為9.82%，到2030年將達到22.6億美元。

5-α 還原酶缺乏症是一種罕見的遺傳性疾病，其特徵是將睪固酮轉化為二氫睪固酮 (DHT) 的酵素存在缺陷，而二氫睪固酮對男性性發育非常重要。市場範圍包括解決這些缺陷的藥物、診斷和治療性介入。它的需求源於它在使模糊的生殖器正常化、澄清性別認同以及管理相關心理後果方面的重要作用。應用領域包括產前診斷、新療法的開發和潛在的基因療法。主要的最終用途領域包括醫院、罕見疾病專科診所和專門從事遺傳疾病的研究機構。

主要市場統計
基準年[2023] 11.7億美元
預測年份 [2024] 12.8億美元
預測年份 [2030] 22.6億美元
複合年成長率（%） 9.82%

市場成長的推動因素包括對罕見遺傳疾病的認知不斷提高、CRISPR 等基因組編輯技術的進步以及醫療保健支出的增加。最新的機會在於個人化醫療，特別是針對個人基因特徵的干涉措施。公司可以透過投資與醫療保健提供者的夥伴關係來加強其市場地位，以促進早期診斷和治療計劃。此外，整合遺傳諮詢服務可以增強對消費者的價值提案。局限性包括該疾病的罕見性，從而限制了臨床試驗和市場投資。圍繞基因編輯的倫理擔憂可能會阻礙某些進步，包括開發新治療方法的高成本和監管核准程序的複雜性。

該領域的創新可以集中在開發非侵入性診斷測試以及利用人工智慧進行預測分析和患者管理解決方案。整合荷爾蒙療法和基因療法的聯合治療的潛力可以為治療功效和業務成長開闢重要途徑。持續關注強力的研究和發展至關重要，促進與學術機構和生物技術部門的合作也很重要。整體而言，該市場尚不發達，但前景廣闊，相關人員需要平衡對創新研究和積極市場推廣的重視，以有效利用成長機會。

市場動態：揭示快速發展的 5α 還原酶缺乏症市場的關鍵市場洞察

5α-還原酶缺乏症市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業減輕政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特五力：駕馭 5α 還原酶缺乏症市場的策略工具

波特的五力框架是了解 5α 還原酶缺乏症市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對 5α 還原酶缺乏症市場的影響

外部宏觀環境因素在塑造 5α-還原酶缺乏症市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解5α還原酶缺乏症市場的競爭狀況

對 5α-還原酶缺乏症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 5α 還原酶缺乏症市場供應商的績效評估

FPNV定位矩陣是評估5α還原酶缺乏症市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 5α-還原酶缺乏症市場的成功之路

對於想要加強在全球市場的影響力的公司來說，對 5α-還原酶缺乏症市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋主要焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 5α-還原酶缺乏症盛行率的增加增加了對先進診斷和治療性介入的需求
      • 提高對遺傳疾病的認知和了解，促進早期診斷和治療
      • 醫療費用上漲和政府努力促進罕見遺傳疾病的研發
      • 創新治療方案和生物技術進步推動 5α-還原酶缺乏症治療的成長
    • 抑制因素
      • 病患意識低落和診斷挑戰阻礙了 5α 還原酶缺乏症市場的成長
    • 機會
      • 利用數位健康技術為 5α-還原酶缺乏症患者建立強大的患者支持網路。
      • 與國際製藥公司合作，快速推動解決5-α還原酶缺乏症新治療方法的臨床試驗
      • 與醫療保健提供者建立夥伴關係並創建綜合護理模式以改善患者的生活品質
    • 任務
      • 嚴格的監管要求和核准流程減緩了新治療方法的採用。 5α還原酶缺乏症市場
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第 6 章 5α 還原酶缺乏症市場：依類型

  • 介紹
  • 原發性5α-還原酶缺乏症
    • 類型1
    • 2型
  • 次發性5α-還原酶缺乏症
    • 獲得的
    • 先天性的

第 7 章 5α 還原酶缺乏症市場：依最終用戶

  • 介紹
  • 診所
  • 醫院
  • 研究所
  • 專門治療中心

第 8 章 5α 還原酶缺乏症市場：依年齡層

  • 介紹
  • 年輕又年輕
  • 成人
  • 兒科的

第 9 章 5α 還原酶缺乏症市場：透過診斷方法

  • 介紹
  • 基因檢測
    • 染色體分析
    • DNA分析
  • 荷爾蒙測試
    • 雙氫睪酮 (DHT) 水平
    • 血清睪固酮水平
  • 放射影像診斷
    • MRI
    • 超音波

第 10 章 5α 還原酶缺乏症市場：依治療分類

  • 介紹
  • 荷爾蒙補充療法
    • 雄激素
    • 雌激素
  • 監測和跟進
  • 心理支持
  • 手術介入
    • 生殖器重組
    • 性腺切除術

第11章北美和南美5α還原酶缺乏症市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區5α還原酶缺乏症市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲5α還原酶缺乏症市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-2B5802CFE14D

The 5-Alpha Reductase Deficiency Market was valued at USD 1.17 billion in 2023, expected to reach USD 1.28 billion in 2024, and is projected to grow at a CAGR of 9.82%, to USD 2.26 billion by 2030.

5-Alpha Reductase Deficiency is a rare genetic condition characterized by a defect in the enzyme responsible for converting testosterone into dihydrotestosterone (DHT), crucial for male sexual development. The market scope involves pharmaceuticals, diagnostics, and therapeutic interventions addressing these deficiencies. The necessity stems from its critical role in normalizing ambiguous genitalia, providing gender identity clarity, and managing associated psychological impacts. Application areas include prenatal diagnostics, novel therapeutic agent development, and potentially gene therapy. Key end-use segments are hospitals, specialized clinics for rare diseases, and research institutions focused on genetic disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 1.17 billion
Estimated Year [2024] USD 1.28 billion
Forecast Year [2030] USD 2.26 billion
CAGR (%) 9.82%

Market growth is propelled by rising awareness about rare genetic conditions, advances in genome editing technologies like CRISPR, and increasing healthcare expenditure. Latest opportunities lie in personalized medicine, particularly in tailoring interventions that suit individual genetic profiles. Companies can bolster their market position by investing in partnerships with healthcare providers to facilitate early diagnosis and therapeutic planning. Additionally, integrating genetic counseling services enhances the value proposition for consumers. Limitations include the rarity of the condition, resulting in limited clinical trials and market investments. Ethical concerns surrounding gene editing could impede certain advancements, while challenging factors include high development costs for novel therapies and procedural complexities in regulatory approvals.

Innovation within this field can pivot towards developing non-invasive diagnostic tests and leveraging artificial intelligence for predictive analytics and patient management solutions. The potential of combination therapies, integrating hormonal treatments with gene therapy, may open significant avenues for treatment efficacy and business growth. Continued focus on robust R&D, alongside fostering collaborations with academic and biotech sectors, is essential. Overall, the market displays a nascent yet promising nature, suggesting that stakeholders need a balanced emphasis on innovative research and active market promotion to capitalize on growth opportunities effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving 5-Alpha Reductase Deficiency Market

The 5-Alpha Reductase Deficiency Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of 5-alpha reductase deficiency raising demand for advanced diagnostic and therapeutic interventions
    • Increasing awareness and better understanding of genetic disorders enhancing early diagnosis and treatment
    • Rising healthcare expenditure and government initiatives promoting research and development in rare genetic conditions
    • Innovative treatment options and biotechnological advancements driving growth in 5-alpha reductase deficiency treatments
  • Market Restraints
    • Limited patient awareness and diagnosis challenges hinder market growth for 5-alpha reductase deficiency
  • Market Opportunities
    • Leveraging digital health technologies to create a robust patient support network for those with 5-alpha reductase deficiency
    • Collaborating with international pharmaceutical companies to fast-track clinical trials for new treatments addressing 5-alpha reductase deficiency
    • Establishing partnerships with healthcare providers for integrated care models to enhance quality of life for 5-alpha reductase deficiency patients
  • Market Challenges
    • Stringent regulatory requirements and approval processes, slowing down the introduction of new treatments in the 5-alpha reductase deficiency market

Porter's Five Forces: A Strategic Tool for Navigating the 5-Alpha Reductase Deficiency Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the 5-Alpha Reductase Deficiency Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the 5-Alpha Reductase Deficiency Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the 5-Alpha Reductase Deficiency Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the 5-Alpha Reductase Deficiency Market

A detailed market share analysis in the 5-Alpha Reductase Deficiency Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the 5-Alpha Reductase Deficiency Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the 5-Alpha Reductase Deficiency Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the 5-Alpha Reductase Deficiency Market

A strategic analysis of the 5-Alpha Reductase Deficiency Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the 5-Alpha Reductase Deficiency Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the 5-Alpha Reductase Deficiency Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Primary 5-Alpha Reductase Deficiency and Secondary 5-Alpha Reductase Deficiency. The Primary 5-Alpha Reductase Deficiency is further studied across Type 1 and Type 2. The Secondary 5-Alpha Reductase Deficiency is further studied across Acquired and Congenital.
  • Based on End Users, market is studied across Clinics, Hospitals, Research Institutes, and Specialty Treatment Centers.
  • Based on Age Group, market is studied across Adolescents, Adults, and Pediatric.
  • Based on Diagnosis Technique, market is studied across Genetic Testing, Hormone Testing, and Radiological Imaging. The Genetic Testing is further studied across Chromosomal Analysis and DNA Analysis. The Hormone Testing is further studied across Dihydrotestosterone (DHT) Levels and Serum Testosterone Levels. The Radiological Imaging is further studied across MRI and Ultrasound.
  • Based on Treatment, market is studied across Hormone Replacement Therapy, Monitoring And Follow-Up, Psychological Support, and Surgical Interventions. The Hormone Replacement Therapy is further studied across Androgens and Estrogens. The Surgical Interventions is further studied across Genital Reconstruction and Gonadectomy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of 5-alpha reductase deficiency raising demand for advanced diagnostic and therapeutic interventions
      • 5.1.1.2. Increasing awareness and better understanding of genetic disorders enhancing early diagnosis and treatment
      • 5.1.1.3. Rising healthcare expenditure and government initiatives promoting research and development in rare genetic conditions
      • 5.1.1.4. Innovative treatment options and biotechnological advancements driving growth in 5-alpha reductase deficiency treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited patient awareness and diagnosis challenges hinder market growth for 5-alpha reductase deficiency
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging digital health technologies to create a robust patient support network for those with 5-alpha reductase deficiency
      • 5.1.3.2. Collaborating with international pharmaceutical companies to fast-track clinical trials for new treatments addressing 5-alpha reductase deficiency
      • 5.1.3.3. Establishing partnerships with healthcare providers for integrated care models to enhance quality of life for 5-alpha reductase deficiency patients
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and approval processes, slowing down the introduction of new treatments in the 5-alpha reductase deficiency market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. 5-Alpha Reductase Deficiency Market, by Type

  • 6.1. Introduction
  • 6.2. Primary 5-Alpha Reductase Deficiency
    • 6.2.1. Type 1
    • 6.2.2. Type 2
  • 6.3. Secondary 5-Alpha Reductase Deficiency
    • 6.3.1. Acquired
    • 6.3.2. Congenital

7. 5-Alpha Reductase Deficiency Market, by End Users

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals
  • 7.4. Research Institutes
  • 7.5. Specialty Treatment Centers

8. 5-Alpha Reductase Deficiency Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescents
  • 8.3. Adults
  • 8.4. Pediatric

9. 5-Alpha Reductase Deficiency Market, by Diagnosis Technique

  • 9.1. Introduction
  • 9.2. Genetic Testing
    • 9.2.1. Chromosomal Analysis
    • 9.2.2. DNA Analysis
  • 9.3. Hormone Testing
    • 9.3.1. Dihydrotestosterone (DHT) Levels
    • 9.3.2. Serum Testosterone Levels
  • 9.4. Radiological Imaging
    • 9.4.1. MRI
    • 9.4.2. Ultrasound

10. 5-Alpha Reductase Deficiency Market, by Treatment

  • 10.1. Introduction
  • 10.2. Hormone Replacement Therapy
    • 10.2.1. Androgens
    • 10.2.2. Estrogens
  • 10.3. Monitoring And Follow-Up
  • 10.4. Psychological Support
  • 10.5. Surgical Interventions
    • 10.5.1. Genital Reconstruction
    • 10.5.2. Gonadectomy

11. Americas 5-Alpha Reductase Deficiency Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific 5-Alpha Reductase Deficiency Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa 5-Alpha Reductase Deficiency Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis International AG
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET RESEARCH PROCESS
  • FIGURE 2. 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. 5-ALPHA REDUCTASE DEFICIENCY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. 5-ALPHA REDUCTASE DEFICIENCY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. 5-ALPHA REDUCTASE DEFICIENCY MARKET DYNAMICS
  • TABLE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONGENITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHROMOSOMAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIHYDROTESTOSTERONE (DHT) LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SERUM TESTOSTERONE LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ANDROGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY MONITORING AND FOLLOW-UP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PSYCHOLOGICAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENITAL RECONSTRUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GONADECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 293. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)

TABLE 29